Loading…
Reported covered position: Office of Rep. McNerney 6/2015 - 2/2017
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program
Source: Senate LDA
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Accelerating Access to Dementia and Alzheimer’s Provider Training Act
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program
Accelerating Access to Dementia and Alzheimer’s Provider Training Act
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Accelerating Access to Dementia and Alzheimer’s Provider Training Act
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Issues related to H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. ORPHAN CURES Act, no current bill number Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Issues related to H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. ORPHAN CURES Act, no current bill number Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Issues related to H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. ORPHAN CURES Act, no current bill number Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act S.3558, BioSecure Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Prohibiting Foreign Access to American Genetic Information Act of 2024
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Prohibiting Foreign Access to American Genetic Information Act of 2024
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act S.3558, BioSecure Act
Prohibiting Foreign Access to American Genetic Information Act of 2024
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Prohibiting Foreign Access to American Genetic Information Act of 2024
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
To prohibit the use of funds for the 2022 and 2026 World Cup until the date on which Policy 604-1 of the United States Soccer Federation is reinstated.
Discussions regarding Medicaid 340B drug discount program Reducing Out-of-Pocket Costs for Biosimilars in Medicare Part B Support for H.R. 6179, Directing CMS to implement a shared savings model for biosimilars
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Issues related to H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. ORPHAN CURES Act, no current bill number Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA), White House Office
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials
Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B progran, no specific bill.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials
Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B progran, no specific bill.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B progran, no specific bill. Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act S.3558, BioSecure Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation, including provisions related to corporate taxes, Medicare, and prescription drug pricing Mental Health Workforce Expansion The Mental Health Professionals Workforce Shortage Loan Repayment Act HELP Copays Act Issues related to ALS
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding coverage, coding, and reimbursement issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding Medicaid 340B drug discount program Reducing Out-of-Pocket Costs for Biosimilars in Medicare Part B Support for H.R. 6179, Directing CMS to implement a shared savings model for biosimilars
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding Medicaid 340B drug discount program Reducing Out-of-Pocket Costs for Biosimilars in Medicare Part B
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of